Department of Pharmacy, Baotou Medical College, Baotou 014040, China.
Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Hohhot 010020, China.
Molecules. 2023 Dec 25;29(1):127. doi: 10.3390/molecules29010127.
The development of liver fibrosis is a result of chronic liver injuries may progress to liver cirrhosis and liver cancer. In recent years, liver fibrosis has become a major global problem, and the incidence rate and mortality are increasing year by year. However, there are currently no approved treatments. Research on anti-liver-fibrosis drugs is a top priority. Dietary polyphenols, such as plant secondary metabolites, have remarkable abilities to reduce lipid metabolism, insulin resistance and inflammation, and are attracting more and more attention as potential drugs for the treatment of liver diseases. Gradually, dietary polyphenols are becoming the focus for providing an improvement in the treatment of liver fibrosis. The impact of dietary polyphenols on the composition of intestinal microbiota and the subsequent production of intestinal microbial metabolites has been observed to indirectly modulate signaling pathways in the liver, thereby exerting regulatory effects on liver disease. In conclusion, there is evidence that dietary polyphenols can be therapeutically useful in preventing and treating liver fibrosis, and we highlight new perspectives and key questions for future drug development.
肝纤维化的发展是慢性肝损伤的结果,可能进展为肝硬化和肝癌。近年来,肝纤维化已成为一个全球性的主要问题,其发病率和死亡率逐年上升。然而,目前尚无批准的治疗方法。抗肝纤维化药物的研究是当务之急。膳食多酚,如植物次生代谢物,具有显著的降低脂质代谢、胰岛素抵抗和炎症的能力,作为治疗肝脏疾病的潜在药物正受到越来越多的关注。逐渐地,膳食多酚成为改善肝纤维化治疗的焦点。人们观察到膳食多酚对肠道微生物组成的影响以及随后产生的肠道微生物代谢物,这些能够间接调节肝脏中的信号通路,从而对肝脏疾病发挥调节作用。总之,有证据表明,膳食多酚在预防和治疗肝纤维化方面可能具有治疗作用,我们强调了未来药物开发的新视角和关键问题。